| INTRODUC TI ON
Influenza and other respiratory viruses account for substantial morbidity in children. [1] [2] [3] [4] [5] The prime strategy for preventing respiratory infection is vaccination against influenza. Protection against influenza with vaccines is approximately 60% effective, but may be lower, particularly when there is a mismatch between antigens in the vaccine and the circulating influenza strains. 6 In the absence of available vaccines against other respiratory viruses, strategies in addition to influenza vaccination may be of clinical benefit to children.
It has been proposed that vitamin D, ingested as cholecalciferol (vitamin D) or ergocalciferol (vitamin D 2 ), can reduce viral respiratory infection, possibly by stimulating expression of antimicrobial peptides, such as the defensin retrocyclin-2. 7, 8 Observational studies in children have demonstrated an association between vitamin D levels and respiratory infection, but have been inconsistent. [9] [10] [11] [12] [13] [14] A recent systematic review and meta-analysis of individual participant data of vitamin D clinical trials of children and adults reported a reduced risk of acute respiratory infection (odds ratio 0.88, 95% CI: 0.81-0.96). 15 Important limitations were that definitions of respiratory infection in children varied considerably (eg, including pneumonia, 16 otitis media, 17 and exacerbation of asthma 18, 19 ) and the vast majority of trials (23 of 25) did not include any laboratory confirmation of respiratory infection. 15, 20 Conducting randomized controlled trials of vitamin D supplementation to prevent influenza and other respiratory infections can be challenging in settings where vitamin D deficiency may not be prevalent and uptake of influenza vaccination is relatively high. 21, 22 In contrast, in most low-and middle-income countries, such as
Vietnam, children are not routinely vaccinated against influenza and vitamin D deficiency in children has been reported to be more prevalent. 23 We conducted a randomized trial of vitamin D in children in Vietnam to assess its effectiveness in reducing laboratory-confirmed influenza and non-influenza viral respiratory tract infections. We hypothesized that vitamin D would reduce both laboratory-confirmed influenza and non-influenza respiratory viral infection compared to placebo.
| ME THODS

| Study design
A placebo-blinded randomized controlled trial. The study was conducted in two phases. In the first phase, we enrolled participants from one commune, Thanh Ha (pop. 9699), in the Thanh Liem district of Ha Nam Province. In the second phase of the trial, we enrolled 
| Participants
We enrolled children and adolescents between the ages of 3 and 
| Randomization and blinding
Participants were assigned at random to one of the two study groups 
| Procedures
Children and adolescents randomized to vitamin D received 7 drops a All hazard ratios were calculated using the participants' first infection with the virus. where the specimens were stored at ≤−70°C. These specimens were batched and then sent to McMaster University.
| Outcomes
The primary outcome of this study was reverse transcriptase (RT)-PCR-confirmed influenza infection using multiplex PCR for influenza A and influenza B (using modified CDC primers for matrix A gene). The coprimary outcome, non-influenza respiratory viral infection, was measured using a separate multiplex PCR for parainfluenza 1, 2, 3, metapneumovirus, RSV, entero-rhinovirus, and adenovirus.
Secondary outcomes included the following: influenza-like illness, defined as cough and fever of ≥38.0°C, receipt of antibiotics, use of over the counter medication for respiratory symptoms, pharmacy visits, private medical clinic visits, and medical center or hospital visits. These outcomes were measured through parental report with confirmation through review of commune health center records when possible.
Research staff monitored for signs and symptoms of toxicity using checklists for symptoms. The major potential toxicity was hypercalcemia which could present as kidney stones. Data on toxicity were recorded monthly.
| Statistical analysis
We calculated our sample size based on the results of the first phase of the study. We had enrolled and randomized 400 participants and followed them over 12 months. Without unblinding this first phase of the trial, we reviewed the results of samples from 260 participants who we had tested by RT-PCR. The results showed that 81 of the 260 (31%) participants had at least one respiratory virus detected and 34 (13%) had influenza detected. We reasoned that by expanding the sample size by another 900 participants for a total of 1300 (650 participants in each group), we would have 80% power to detect a 40% risk reduction for influenza and 80% power to detect a 25% risk reduction due to vitamin D for all other respiratory viruses.
For PCR-confirmed influenza and non-influenza respiratory infection, we conducted a time-to-event analysis using Cox proportional hazards for laboratory-confirmed influenza and for non-influenza respiratory viruses. To avoid lack of independence associated with counting multiple outcomes, each of these outcomes in a participant was only counted once.
The secondary outcomes were treated as being dichotomous, that is, the occurrence or receipt of ≥1 of the following: influenza-like illness, a course of antibiotics, pharmacy visit, over the counter medication for respiratory symptoms, private medical clinic visits, and hospital or medical center visits. For each of these secondary dichotomous outcomes, we estimated the absolute risk difference of the vitamin D
effect.
We planned to analyze participants in the group to which they were assigned in case of crossovers. P values and 95% confidence intervals were calculated with 2-tailed tests. Since the type 1 error was split between the two primary outcomes, differences with P < 0.025 for 2-tailed tests were considered significant for these outcomes.
TA B L E 3 The distribution of RT-PCR-confirmed respiratory viral infection in participants by vitamin D group and placebo group
For all other outcomes, differences with P < 0.05 were considered significant. Statistical analyses were conducted using sas version 9.2 (SAS Institute, Cary, NC) and R version 3.2.
| Patient involvement
No patients were involved in the design of the research question, study design, or outcome measures. Because of patient preference, we did use oropharyngeal as opposed to nasopharyngeal swabs. A summary of the vitamin D levels was disseminated to participants.
| RE SULTS
| Participants
There were 1641 children and adolescents assessed for eligibility in two Characteristics of enrolled participants are shown in Table 1 .
The mean age of participants was 8.5 years (standard deviation
[SD] 4.0 years); 52.2% were female; and both figures were similar between the two study groups (Table 1) 
| Outcomes
We observed RT-PCR-confirmed influenza A or B in 50 children (7.7%) in the vitamin D group and in 43 children (6.6%) in the placebo group (Table 2) . Of these, 67 (72.0%) had influenza A, 24 (28.8%) had influenza B, and 2 (2.2%) had both influenza A and B. Non-influenza respiratory virus infection occurred in 146 (22.5%) in the vitamin D group and in 185 (28.5%) in the placebo group (Table 3) . There were a total of 177 (27.2%) influenza and non-influenza respiratory viruses in the vitamin D group and 209 (32.2%) in the placebo group.
We found no significant difference between vitamin D and placebo groups for RT-PCR-confirmed influenza, hazard ratio [HR]:
1.18, 95% CI: 0.79-1.77 ( Figure 2 ). We found that vitamin D significantly reduced non-influenza respiratory viral infection, HR: 0.76, 95% CI: 0.61-0.94 (P = 0.011). Although the attack rates differed between the two stages of the study, the relationship between the two groups was similar (Table 2) . When considering all respiratory viruses, including influenza, the effect of vitamin D in reducing infection was significant, HR: 0.81, 95% CI: 0.66-0.99.
When we compared the vitamin D group to the placebo group for secondary outcomes, we found the following: 50 (7.7%) vs 62 (9.5%) with ≥ 1 episodes of influenza-like illness (absolute difference −1.8%, 95% CI: −4.9%-1.2%), 270 (41.5%) vs 282 (43.4%) who received ≥ 1 course of antibiotics (absolute difference −1.85%, 95%
CI: −7.2%-3.5%), 245 (37.7%) vs 251 (38.6%) that visited a pharmacy because of respiratory infection (absolute difference −0.92%, 95%
CI: −6.2%-4.4%), and 338 (52.0%) vs 361 (55.5%) that used over the counter medications for respiratory infection (absolute difference −3.5%, 95% CI: −9.0%-1.9%). No significant difference in these outcomes between groups was found. Only two participants in each group visited a private clinic, and only one in the vitamin D group and two in the placebo visited a hospital or medical center for respiratory symptoms. Only one serious adverse event was reported, which was not related to the study, a hospitalization for a scheduled tonsillectomy.
We conducted a post hoc subgroup analysis limited to participants who at baseline had 25OHD levels less than 50 nmol/L. In this cohort, there were only 14 cases of influenza, and the hazard ratio was 2.5 (5% CI: 0.78-7.9), P = 0.12. When we conducted the analysis using other respiratory viruses as the outcome, there were 46 events, HR: 0.92, 95% CI: 0.52-1.66, P = 0.8.
| D ISCUSS I ON
We found that vitamin D supplementation of 14 000 U/wk for 8 months had no significant effect on confirmed influenza infection in healthy children and adolescents between the ages of 3 and 17 years in Vietnam. However, supplementation significantly reduced RT-PCRconfirmed non-influenza respiratory viral infections by about 25%.
| Strengths and limitations of the study
Strengths of the study were that it was a randomized placebocontrolled trial with laboratory-confirmed respiratory viral infection as the main outcome and measurement of vitamin both at baseline and at follow-up.
One possible limitation was the use of oropharyngeal specimens instead of nasopharyngeal specimens. This was based on adherence to testing, and we reasoned that an increase in the number of swabs would make up for any reduction in sensitivity. The attack rate for all respiratory viruses in our study was 35%, which is comparable to other studies that have used RT-PCR to detect infection in children. [24] [25] [26] A study in the same population in Vietnam reported similar attack rates as ours. 23 Also, detection of the types of viruses and their relative frequency was similar to previous reports. The most common noninfluenza respiratory virus we detected was entero-rhinovirus, consistent with other studies. [24] [25] [26] In our study, the ratio of attack rates for vitamin D to placebo for entero-rhinovirus, 0.83, represented the median effect for non-influenza respiratory viruses, which ranged from 0.47 for human metapneumovirus to 1.17 for parainfluenza viruses 1-3.
Only 17% of participants in our study had vitamin D levels <50 nmol/L, in contrast to a previous study from Vietnam where >50% children had insufficiency or deficiency. 
| Comparison with other studies
Two previous trials of vitamin D in children reported either an effect of vitamin D on all respiratory viruses or no effect on all influenza. 28 
| CON CLUS ION
Our results show that vitamin D supplementation does not reduce influenza but can reduce non-influenza respiratory infections in children and adolescents aged 3-17 years in a low-and middleincome country. Our findings imply that vitamin D supplementation can play a moderate role in reducing illness caused by respiratory viruses. 
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